Cytidine deaminase polymorphisms and worse treatment response in normal karyotype AML

Lyoung Hyo Kim, Hyun Sub Cheong, Youngil Koh, Kwang Sung Ahn, Chansu Lee, Hyung Lae Kim, Hyoung Doo Shin, Sung Soo Yoon

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


The cytidine deaminase (CDA) catalyzes the irreversible hydrolytic deamination of the cytarabine (AraC) into a 1-β-D-Arabinofuranosyluracil (AraU), an inactive metabolite that plays a crucial role in lowering the amount of AraC, a key chemotherapeutic drug, in the treatment of patients with acute myeloid leukemia (AML). In this study, we hypothesized that CDA polymorphisms were associated with the AraC metabolism for AML treatment and/or related clinical phenotypes. We analyzed 16 polymorphisms of CDA among 50 normal karyotype AML (NK-AML) patients, 45 abnormal karyotype AML (AK-AML) patients and 241 normal controls (NC). Several polymorphisms and haplotypes, rs532545, rs2072671, rs471760, rs4655226, rs818194 and CDA-ht3, were found to have a strong correlation with NK-AML compared with NC and these polymorphisms also revealed strong linkage disequilibrium with each other. Among them, rs2072671 (79A>C), which is located in a coding region and the resultant amino acid change K27Q, showed significant associations with NK-AML compared with NC (P=0.009 and odds ratio=2.44 in the dominant model). The AC and CC genotypes of rs2072671 (79A>C) were significantly correlated with shorter overall survival rates (P=0.03, hazard ratio=1.84) and first complete remission duration (P=0.007, hazard ratio=3.24) compared with the AA genotype in the NK-AML patients. Our results indicate that rs2072671 in CDA may be an important prognostic marker in NK-AML patients.

Original languageEnglish
Pages (from-to)749-754
Number of pages6
JournalJournal of Human Genetics
Issue number12
StatePublished - 1 Dec 2015

Bibliographical note

Publisher Copyright:
© 2015 The Japan Society of Human Genetics All rights reserved.


Dive into the research topics of 'Cytidine deaminase polymorphisms and worse treatment response in normal karyotype AML'. Together they form a unique fingerprint.

Cite this